This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zohar, S. Articles by Chevret, S. Search for Related Content PubMed PubMed Citation Articles by Zohar, S. Articles by Chevret, S. Social Bookmarking                         What's this?

Quality assessment of phase I dose-finding cancer trials: proposal of a checklist

Inserm U717, Hôpital Saint Louis, Paris, France, Inserm CIC 9504, Centre d'Investigations Cliniques, AP-HP, Hôpital Saint Louis, Paris, France, sarah.zohar{at}univparis-diderot.fr

Qing Lian

Département de Biostatistique et Informatique Médicale, AP-HP, Hôpital Saint Louis, Paris, France

Vincent Levy

Inserm U717, Hôpital Saint Louis, Paris, France, Inserm CIC 9504, Centre d'Investigations Cliniques, AP-HP, Hôpital Saint Louis, Paris, France

Ken Cheung

Department of Biostatistics, Mailman School of Public Health, Columbia University, New-York, NY, U.S.A

Anastasia Ivanova

Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, U.S.A

Sylvie Chevret

Inserm U717, Hôpital Saint Louis, Paris, France, Département de Biostatistique et Informatique Médicale, AP-HP, Hôpital Saint Louis, Paris, France

Background Qualitative checklists for phase III trials have been proposed, to improve the reporting of such trials and to assess the validity of their results.

Purpose Our objective was to develop such a scale for phase I cancer trials.

Methods From a review of existing guidelines and checklists for phase III clinical trials, a staff team was responsible for the first selection of items and the construction of the questionnaire. The proposed quality assessment measures were rated by the survey respondents comprised of phase I research clinicians and statisticians on a 4-point Likert scale. Selected items from the quantitative analysis of the questionnaires were reviewed by an expert team who was responsible for providing the final items list. This was then applied to 103 recently published cancer phase I trials.

Results Of the 48 initial items proposed by the staff team, 17 were selected from the quantitative analysis of the 99 participants' ratings. After qualitative analysis by the expert team, a 15-item checklist was derived, with 5 items related to trial objective, 5 to design, and 5 to analysis. The application to 103 recent journal articles on phase I cancer trials evaluating cytotoxic drugs showed on average the report of 10 items (range: 6—13) with 4 items reported in more than 95% of papers, while 2 were poorly reported.

Limitations The response rate of participants was 20.7%.

Conclusions A quality assessment checklist was developed for improved critical appraisal of the reporting of cytotoxic, dose-finding phase I oncology trials. This may be a first step toward a minimum standard of quality measures for all phase I clinical trial reports. Clinical Trials 2008; 5: 478—485. http://ctj.sagepub.com

Clinical Trials, Vol. 5, No. 5, 478-485 (2008)
DOI: 10.1177/1740774508096653


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?